Joshua Thaden is an Infectious Disease physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
40 Duke Medicine Circle
Clinic 1k
Durham, NC 27710
Telephone
919-668-3197Registry record last updated 7 Dec 2018.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
58.7%Tetracycline-class Drug9.6%Doxycycline Hyclate100%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor7.2%Triumeq100%Part D<11 patients+ 7 more classes in this area
Nervous system
29.3%SSRI12.5%Trazodone Hcl100%Part D<11 patientsAntihistamine6.2%Hydroxyzine Hcl100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
12%ACE inhibitor6.2%Lisinopril100%Part D<11 patientsThiazide diuretic5.8%Hydrochlorothiazide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
Duke University
FY2026$172,076K08AI171183 - Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
Duke University
FY2025$174,225K08AI171183 - Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
Duke University
FY2024$177,981K08AI171183
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”